At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own treatment, Eli Lilly said of the results presented at the European Congress on Obesity and published in the New England Journal of Medicine.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

One weight loss injection has been branded more effective than another, after scientists carry out the first ever head-to-head trial of Mounjaro and Wegovy.